Among T2 Diabetes patients with Poorly Controlled Lipid Levels, Early Statin Initiation reduces Renal disease risk

Written By :  Dr.Niharika Harsha B
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-07-11 05:00 GMT   |   Update On 2023-07-11 10:16 GMT

Recent research revealed that early initiation of statins effectively reduces the risk of renal disease in T2 diabetics who are at risk of developing renal disease and need immense control of lipoproteins. The study was published in the Canadian Medical Association Journal.Diabetic kidney disease (DKD) is a common microvascular complication in patients with type 2 diabetes causing an...

Login or Register to read the full article

Recent research revealed that early initiation of statins effectively reduces the risk of renal disease in T2 diabetics who are at risk of developing renal disease and need immense control of lipoproteins. The study was published in the Canadian Medical Association Journal.

Diabetic kidney disease (DKD) is a common microvascular complication in patients with type 2 diabetes causing an enormous burden physically and financially. Dyslipidemia is one of the risk factors for diabetic kidney disease. Statins are the most common medications that reduce the cardiovascular risk in patients with type 2 diabetes and hypertension. Though guidelines recommend the use of statins for diabetic patients who are 40 years or older, some literature has shown worsening glycemic control progressing the microvascular diseases. As there is uncertainty about prescribing statins for diabetic kidney disease, researchers conducted a multicentre retrospective cohort study to determine the relationships between statin initiation and kidney outcomes in patients with type 2 DM.

Using a new-user design from the China Renal Data System database, patients with type 2 DM who were aged 40 years or older and admitted to the hospital between Jan. 1, 2000, and May 26, 2021, were included. Any patients with pre-existing chronic kidney disease and those who were already on statins or without follow-up at an affiliated outpatient clinic within 90 days after discharge were excluded. The primary exposure was the initiation of a statin.

The outcomes of the measurements were:

Primary outcome -

occurrence of kidney dysfunction estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2 and > 25% decline from baseline) and

proteinuria (a urinary albumin-to-creatinine ratio ≥ 30 mg/g and > 50% increase from baseline), sustained for at least 90 days

secondary outcomes

development of kidney function decline (a sustained > 40% decline in eGFR)

Cox proportional hazards regression was used to evaluate the relationships between statin initiation and kidney outcomes, as well as to conduct subgroup analyses according to patient characteristics, presence or absence of dyslipidemia, and pattern of dyslipidemia. The association between different levels of lipid control and outcomes was explored for statin initiators. Analyses were conducted using propensity overlap weighting to balance the participant characteristics.

Key findings:

  • Among 7272 statin initiators and 12,586 non initiators in the weighted cohort, statin initiation was associated with lower risks of incident DKD and kidney function decline.
  • Similar results were obtained in the primary analyses for participants with differing patterns of dyslipidemia, those prescribed different statins, and after stratification according to participant characteristics.
  • Among statin initiators, those with intensive control of high-density lipoprotein cholesterol (LDL-C) (< 1.8 mmol/L) had a lower risk of incident DKD than those with inadequate lipid control (LDL-C ≥ 3.4 mmol/L).

Thus, statin initiation was associated with significantly lower risks of developing DKD and kidney function decline. These relationships were strong and unaffected by variations in clinical traits or dyslipidemia patterns.

Further reading: Shiyu Zhou et al. Statin initiation and risk of incident kidney disease in patients with diabetes. https://doi.org/10.1503/cmaj.230093

Tags:    
Article Source : Canadian Medical Association Journal

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News